scholarly journals The impact of the HPV vaccine on the world: initial outcomes and challenges

2020 ◽  
Vol 32 ◽  
Author(s):  
Daniel Vitorino Ribeiro ◽  
Edison Natal Fedrizzi ◽  
Sérgio Murillo Steffens
Keyword(s):  
Hpv Vaccine ◽  
Precancerous Lesions ◽  
Hpv Vaccination ◽  
Real Life ◽  
Genital Warts ◽  
Hpv Infection ◽  
Vaccination Programs ◽  
The World ◽  
Free Search ◽  
The Impact

Introduction: Human papillomavirus (HPV) infection can be considered an epidemic in the world and in Brazil. This infection accounts for virtually all cases of cervical cancer, most malignant anal, vaginal and oropharyngeal tumors, and a large number of cases of cancer of the penis and vulva. The most effective way to prevent this infection is through vaccination. Several countries, including Brazil, have already introduced this vaccine into the public vaccination programs and are observing the real-life results of decreasing HPV-associated diseases. Objective: To evaluate the effectiveness of HPV vaccination in preventing virus-induced diseases in countries that have adopted it for a longer time, in a different scenario from clinical studies. Methods: This is a bibliographic review study in journal databases PubMed, LILACS, SciELO and Scopus, with publications dated from 2000 to 2019. The research was restricted to articles in English and Portuguese and studies conducted in humans. Ten studies that were considered relevant were selected. Furthermore, additional articles found by free search were selected. After this phase, the chosen publications were obtained in full for reassessment of their methodology and results. Results: The HPV vaccine demonstrated its effectiveness in reducing the incidence of HPV infection and/or anogenital warts and/or precancerous lesions in the seven countries analyzed by the study: Australia, Brazil, Denmark, United States of America, New Zealand, Czech Republic and Sweden. The impact was bigger in countries that introduced it earlier, such as Australia, where the vaccine virtually eliminated the incidence of genital warts in women aged under 21 years. Although Brazil implemented the vaccine a few years ago, a preliminary study was conducted in Campos dos Goytacazes, RJ, where the vaccine was implemented in 2010, showing a 55% reduction in the incidence of genital warts for women aged under 21 years old, between 2007 and 2012. Conclusion: The HPV vaccine is highly effective in protecting against HPV infection and disease in the countries where it has been implemented, with better results than those seen in clinical trials.

scholarly journals Assessment of the State of Knowledge about HPV Infection and HPV Vaccination among Polish Resident Doctors

2021 ◽  
Vol 18 (2) ◽  
pp. 551
Author(s):  
Katarzyna Smolarczyk ◽  
Wojciech Pieta ◽  
Slawomir Majewski
Keyword(s):  
Human Papillomavirus ◽  
Primary Prevention ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Hpv Infection ◽  
The State ◽  
Vaccination Programs ◽  
Gynecology And Obstetrics ◽  
Hpv Types ◽  
The Impact

HPV (human papillomavirus) vaccinations have been introduced into the population of many countries through vaccination programs, although their acceptance varies from country to country, largely dependent on the state of knowledge about diseases caused by genital HPV types as well as cultural, social, and religious factors. The aim of the study was to analyze the state of knowledge about HPV and HPV vaccines among doctors during their specialization in gynecology and obstetrics, dermatology and venereology, and pediatrics. Another objective of the study was to analyze the impact of the state of knowledge about HPV vaccination on their attitude to primary prevention, i.e., vaccinations. A questionnaire was used to collect the data and 639 doctors took part in the study. The analysis was carried out mainly using descriptive statistical methods. In Poland, doctors’ knowledge about HPV is low, independent of gender, age, and subject of specialization. Doctors’ knowledge about the HPV vaccine is very low and independent of sex, age, and subject of specialization. However, doctors’ knowledge about HPV and the HPV vaccine influences the attitude to HPV vaccination and does not affect pro-active behaviors.

Review of Evidence and Recommendation for Human Papillomavirus (HPV) Vaccination of Canadian Males Over the Age of 26 Years

2020 ◽  
Vol 24 (3) ◽  
pp. 285-291 ◽  
Author(s):  
Alex Derstenfeld ◽  
Kyle Cullingham ◽  
Zhuo Cai Ran ◽  
Ivan V. Litvinov
Keyword(s):  
Human Papillomavirus ◽  
Sexually Transmitted Infection ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Older Men ◽  
Hpv Infection ◽  
Transmitted Infection ◽  
Vaccination Programs ◽  
Sexually Transmitted ◽  
Control And Prevention

Human papillomavirus (HPV) remains the most common sexually transmitted infection with a lifetime incidence of over 75%. Based on US data from the Centers for Disease Control and Prevention (CDC), 64% of invasive HPV-associated cancers are attributable to HPV 16 or 18 (65% for females; 63% males) and may be prevented by vaccination with either the quadrivalent or nonavalent HPV vaccine. Public HPV vaccination programs are now the norm for women aged 9-45 years and men aged 9-26 years in Canada. Yet, only recently have guidelines begun to consider vaccination of men older than 26 years of age. There now exist compelling reasons to recommend vaccination against HPV amongst males >26 years of age. Recognizing that the risks posed by HPV infection persist beyond 26 years of age, that the vaccination of men aged 26-45 years with HPV vaccine confers immunogenicity at levels demonstrably efficacious against HPV-related diseases, and that the Food and Drug Administration recently expanded the HPV vaccination to include older men, it is argued that HPV vaccination in men older than 26 years of age should be routinely recommended.

scholarly journals Impact of indirect education on knowledge and perception on cervical cancer and its prevention among the parents of adolescent girls: an interventional school-based study

2021 ◽  
Vol 9 ◽  
pp. 251513552199026
Author(s):  
Rony Abraham Jacob ◽  
Priya Srambical Abraham ◽  
Feba Rachel Thomas ◽  
Vytila Navya ◽  
Juny Sebastian ◽  
...  
Keyword(s):  
Adolescent Girls ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Hpv Infection ◽  
South Indian ◽  
Informed Consent Form ◽  
Percentage Improvement ◽  
Indian City ◽  
Study Population ◽  
The Impact

Background: India has almost 225 million adolescent girls and they seem to be at a disadvantage, both economically and by their lack of knowledge on human papilloma virus (HPV) vaccine, when compared to adolescent girls of other Asian countries. Aim: To assess the prevalence of HPV vaccination and to identify the impact of education in improving the knowledge and perception about the HPV infection and vaccination among the parents of adolescent girls. Methodology: The prospective interventional study was conducted in four schools within a South Indian City, Mysuru. The informed consent form and the questionnaire were sent home with the identified adolescent girls during the pre-interventional phase. Educational sessions were conducted for the students in their school and an education leaflet was distributed to their parents. Three weeks later, questionnaires were re-administered to the parents via the enrolled girls and their responses were collected. Results: The prevalence of HPV vaccination in the study population was 4.4%. There was a statistically significant improvement in knowledge in the post-interventional phase of the study ( p = 0.001), but could not identify a significant change in their perception ( p = 0.479). Parents belonging to the socioeconomic class of upper middle and upper lower showed better improvement at the end of the study, with a percentage improvement of 58.93% and 48.44%, respectively. Conclusion: The study proved that the healt care professional can target school children to communicate effectively to their parents on the importance of HPV vaccine as the study clearly observed a positive behavioral change among the study population.

scholarly journals A Systematic Review of Interventions to Improve HPV Vaccination Coverage

Vaccines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 687
Author(s):  
Edison J. Mavundza ◽  
Chinwe J. Iwu-Jaja ◽  
Alison B. Wiyeh ◽  
Blessings Gausi ◽  
Leila H. Abdullahi ◽  
...  
Keyword(s):  
Vaccination Coverage ◽  
Financial Incentives ◽  
Hpv Vaccination ◽  
The United States ◽  
Hpv Infection ◽  
World Health ◽  
Cochrane Central Register ◽  
Transmitted Infection ◽  
Vaccination Programs ◽  
The World

Human papillomavirus (HPV) infection is the most common sexually transmitted infection worldwide. Although most HPV infections are transient and asymptomatic, persistent infection with high-risk HPV types may results in diseases. Although there are currently three effective and safe prophylactic HPV vaccines that are used across the world, HPV vaccination coverage remains low. This review evaluates the effects of the interventions to improve HPV vaccination coverage. We searched the Cochrane Central Register of Controlled Trials, PubMed, Web of Science, Scopus, and the World Health Organization International Clinical Trials Registry Platform and checked the reference lists of relevant articles for eligible studies. Thirty-five studies met inclusion criteria. Our review found that various evaluated interventions have improved HPV vaccination coverage, including narrative education, outreach plus reminders, reminders, financial incentives plus reminders, brief motivational behavioral interventions, provider prompts, training, training plus assessment and feedback, consultation, funding, and multicomponent interventions. However, the evaluation of these intervention was conducted in high-income countries, mainly the United States of America. There is, therefore, a need for studies to evaluate the effect of these interventions in low-and middle-income countries, where there is a high burden of HPV and limited HPV vaccination programs.

scholarly journals Vaccination against HPV: Theoretical Aspects and Practical Results of Cervical Cancer Prevention

2020 ◽  
Vol 18 (6) ◽  
pp. 98-108
Author(s):  
N. V. Zarochentseva ◽  
O. I. Trushina ◽  
E. G Novikova ◽  
I. I. Baranov ◽  
P. D. Lopukhov ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Precancerous Lesions ◽  
Hpv Vaccination ◽  
Well Being ◽  
Hpv Infection ◽  
Research Area ◽  
Cervical Cancer Prevention ◽  
Steady Increase ◽  
Vaccination Programs

Relevance. Cervical cancer (CC) continues to be the focus of attention of oncologists all over the world due to the fact that the incidence of it over the past decades has not tended to decrease. The steady increase in morbidity, high mortality rates, and the tendency to «rejuvenate» the disease, the relatively low detection rate of the early stages of the disease due to poor results of cytological screening predetermine the search for new scientifically based approaches to solving cervical cancer problems. A promising direction for the prevention of squamous cell carcinoma and adenocarcinoma associated with human papillomavirus (HPV) is prophylactic vaccination against HPV, the need for which is due to the role of HPV infection in carcinogenesis processes.The aim of this article is to summarize the currently available data on advances in the prevention of precancerous lesions and cervical cancer, primarily through vaccination against HPV infection.Conclusions. The creation of vaccines for the prevention of oncogenic HPV types is a significant achievement in the biomedical research area. The successful development of a group of vaccines, which can confidently be called the vaccines of the 21st century, gives us hope that modern medicine has the potential to reduce population cancer risk and reduce the likelihood of early onset of cervical cancer. Demonstration of the efficacy and feasibility of routine HPV vaccination programs in a number of countries demonstrates encouraging progress in solving cervical cancer problems. Vaccination against HPV will not only ensure epidemiological well-being, but also lead to a decrease in morbidity and mortality from such a terrible complication of human papillomavirus infection – cervical cancer.

scholarly journals The Role of Vaccination Interventions to Promote HPV Vaccine Uptake Rates in a College-Aged Population: a Systematic Review

2020 ◽  
Author(s):  
Lihong Ou ◽  
Shawn D. Youngstedt
Keyword(s):  
Systematic Review ◽  
Young Adults ◽  
Hpv Vaccine ◽  
Vaccine Coverage ◽  
Hpv Vaccination ◽  
Transmitted Disease ◽  
Hpv Infection ◽  
Vaccine Uptake ◽  
Vaccination Programs ◽  
Aged Population

Abstract This systematic review provided synthesized evidence regarding the effectiveness of the interventions promoting the human papillomavirus (HPV) vaccination in college-aged population. The HPV infection is the most prevailing sexually transmitted disease. Despite the availability and effectiveness of the 9-Valent HPV vaccine, the vaccine coverage among young adults remained low. In witness to the increasing burden of HPV-related infections and cancers, research focused on the vaccination interventions should be conducted to determine the effectiveness of the vaccination strategy and address the gap. The search was conducted through PubMed, Cochrane, and CINAL. Studies were included if they (1) included vaccination programs, (2) target population was young adults aged 17–26, (3) examined factors associated with the intervention effectiveness, (4) were published in English, and (5) were published between February 2010 and February 2020. HPV-related knowledge and intentions toward HPV vaccination were all reported increased after the intervention. Increased HPV vaccination intentions were found associated with the increased vaccine initiation and completion. Among bisexual or homosexual individuals, females were found more likely to complete the HPV dose 2 and 3. The review findings suggested using vaccination interventions incorporated with educational components to promote vaccine uptake among young adults. Supportive interventions tailored to different populations and settings are crucial to address the suboptimal HPV-related knowledge and vaccination status among the young beneficiaries.

scholarly journals The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?

2018 ◽  
Vol 23 (41) ◽  
Author(s):  
Cyra Patel ◽  
Julia ML Brotherton ◽  
Alexis Pillsbury ◽  
Sanjay Jayasinghe ◽  
Basil Donovan ◽  
...  
Keyword(s):  
Vaccination Programme ◽  
Disease Burden ◽  
Hpv Vaccination ◽  
Genital Warts ◽  
Hpv Infection ◽  
High Coverage ◽  
Related Disease ◽  
Hpv Prevalence ◽  
Vaccine Type ◽  
The Impact

Background: A National human papilloma virus (HPV) Vaccination Programme for the prevention of HPV infection and associated disease using the quadrivalent HPV vaccine (4vHPV) has been funded and implemented in Australia since 2007, initially for girls only and extended to boys in 2013, with uptake rates among the highest observed worldwide. Aim: We report on the impact of this national programme on HPV prevalence and associated disease burden and estimate the potential impact of adopting a nonavalent HPV (9vHPV) vaccine. Methods: We performed a non-systematic literature review of studies measuring the burden of HPV-associated disease and infection in Australia before and after introduction of HPV vaccination. We also included key national reports with estimates of HPV-related disease burden. Results: Substantial declines in high-grade cervical disease and genital warts among vaccine-eligible women have been observed. Reductions in genital warts incidence and HPV prevalence among heterosexual men of similar age were observed before introduction of the male vaccination programme, indicating a substantial herd effect. 9vHPV vaccine is expected to prevent up to 90% of cervical and 96% of anal cancers. Of an estimated 1,544 HPV-associated cancers in 2012, 1,242 would have been preventable by the 4vHPV vaccine and an additional 187 anogenital cancers by the 9vHPV vaccine. Conclusions: Vaccination using 4vHPV vaccine has had a large demonstrable impact on HPV-related disease in Australia. A switch to 9vHPV could further reduce the HPV-associated cancer burden. With continued high coverage among both males and females, elimination of vaccine-type HPV disease seems achievable in Australia.

scholarly journals Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean

2017 ◽  
Vol 41 ◽  
pp. 1 ◽  
Author(s):  
Fernando De la Hoz Restrepo ◽  
Nelson Alvis Guzman ◽  
Alejandro De la Hoz Gomez ◽  
Cuauhtémoc Ruiz
Keyword(s):  
Cervical Cancer ◽  
Latin America ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Age Groups ◽  
Hpv Infection ◽  
Birth Cohorts ◽  
Vaccination Programs ◽  
The Caribbean ◽  
Dose Scheme

Objectives. Three highly effective vaccines are available to prevent human papillomavirus (HPV) infection, and they have been introduced in many countries around the world. This article describes advances and challenges in introducing HPV vaccines in the Expanded Program of Immunization (EPI) of countries in Latin America and the Caribbean (LAC). Methods. We reviewed national and regional sources of information to identify LAC countries with and without universal HPV vaccination, along with the year of introduction, type of HPV vaccine, vaccination scheme, age groups targeted, and coverage level reached. Incidence rates of cervical cancer were compared across countries with and without an HPV vaccination program, in order to identify inequities in access to HPV vaccines. Results. So far, 10 LAC countries have supplied data on their vaccination policies and vaccination coverage rates to the Pan America Health Organization. The majority of those 10 started their vaccination programs using quadrivalent vaccine. Only Chile, Ecuador, and Mexico started their programs using a two-dose scheme. However, by the end of 2016, most of the other countries had switched from a three-dose to a two-dose scheme. Different age groups are targeted in the various programs. Some countries vaccinate one-year birth cohorts, while others vaccinate multiple-year birth cohorts. By the end of 2014, coverage with at least two doses ranged from a low of 2% to a high of 86%. With the exception of Venezuela, the LAC countries with the largest populations introduced universal HPV vaccination between 2010 and 2014. Despite the progress that has occurred in some LAC countries, there are still 10 LAC nations with cervical cancer rates above the LAC average (21.2 cases per 100 000) that have not introduced an HPV vaccine in their EPI.Conclusions. With several key adjustments, HPV vaccination programs across Latin America and the Caribbean could be substantially strengthened. Ongoing monitoring of HPV infection outcomes is needed in order to assess the impact of different vaccination policies.

scholarly journals HPV VACCINATION: INCREASING PARENTAL AWARENESS ON PREVENTING CANCER IN THEIR CHILDREN

2019 ◽  
Author(s):  
Adeola Areo ◽  
Kia Crawford ◽  
Chichy Nwachukwu
Keyword(s):  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Anal Intercourse ◽  
The United States ◽  
Genital Warts ◽  
Hpv Infection ◽  
Parental Awareness ◽  
Routine Administration ◽  
Catch Up ◽  
Almost All

HPV is responsible for almost all cervical, anal, oropharynx, penile, vaginal cancers and 90% of genital warts (Rahman, Laz, McGrath, & Berenson, 2014). HPV infection often occurs shortly after initiation of sexual activity. In one study of college-aged women, the cumulative incidence of any HPV infection at 1 year after sexual intercourse was 28.5%, and increased to almost 50% by 3 years (Wang & Palefsky, 2015). HPV is usually transmitted through vaginal or anal intercourse, but it can occur through oral-genital or genital-genital contact as well (Wang & Palefsky, 2015). Currently in the United States, there are three vaccines approved for the prevention of HPV. The Advisory Committee for Immunization Practices (ACIP) recommends routine administration of HPV vaccine at ages 11 and 12 for girls and boys, with catch-up vaccinations through age 26 for females and age 21 for males.

scholarly journals Surgical Treatment of Vulvar HSIL: Adjuvant HPV Vaccine Reduces Recurrent Disease

Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 83
Author(s):  
Alessandro Ghelardi ◽  
Roberto Marrai ◽  
Giorgio Bogani ◽  
Francesco Sopracordevole ◽  
Paola Bay ◽  
...  
Keyword(s):  
Surgical Treatment ◽  
Hpv Vaccine ◽  
Recurrent Disease ◽  
Current Knowledge ◽  
Hpv Vaccination ◽  
Clinical Effectiveness ◽  
Hpv Infection ◽  
Control Group ◽  
Hpv Test ◽  
Significant Difference

Data suggest that adjuvant human papillomavirus (HPV)-vaccination in women treated for cervical HPV diseases reduces recurrent disease. This study investigates adjuvant HPV-vaccination and the rate of recurrence in women undergoing surgery for vulvar high-grade squamous intraepithelial lesions (HSIL). From January 2013 to April 2020, we enrolled 149 women in a prospective case-control study. The control group (NV-group) was treated by standard surgery alone, while the study group received adjuvant vaccination soon after surgery (V-group). A follow-up was performed by vulvoscopy and HPV test. Statistical analysis was performed by Fisher’s exact test. HSIL recurrence was observed in 24/76 (32%) patients in NV-group and in 8/42 patients (19%) of the vaccinated group. By analysing the recurrence rate related to the incident and reactivated latent HPV infection, we found a significant difference between (17/76) 22.3% in NV-group and (2/42) 4.8% in V-group (p = 0.01). A reduction of 78.5% in incident/reactivated HPV infections was demonstrated. Data results add to the current knowledge about the mechanism of post-surgical adjuvant HPV vaccination. Our prospective study is the first to document the vaccine clinical effectiveness in preventing “reactivation” of latent HPV infections. Quadrivalent HPV vaccine administered after the surgical treatment for vulvar HSIL appears to be useful in preventing recurrent disease.

Sign in / Sign up

Export Citation Format

Share Document